重组人生长激素治疗矮小症的临床疗效及其相关因素的影响作用  

Clinical efficacy of recombinant human growth hormone in the treatment of short stature and influence of related factors

作　　者：刘舒慧 占文君 罗灵 LIU Shuhui;ZHAN Wenjun;LUO Ling(Department of Child Endocrinology(PediatricWard 4),Jingdezhen Maternal and Child Health Hospital,Jingdezhen,Jiangxi,333000,China)

机构地区：[1]江西省景德镇妇幼保健院儿童内分泌科(儿科四病区),江西景德镇333000

出　　处：《当代医学》2022年第29期32-34,共3页Contemporary Medicine

摘　　要：目的探讨重组人生长激素(rhGH)治疗矮小症的临床疗效及其相关因素的影响作用。方法选取2019年2月至2020年6月本院收治的76例矮小症患儿作为研究对象,按照随机数字表法分为观察组与对照组,每组38例。对照组采用常规方式治疗,观察组在对照组基础上采用rhGH治疗,比较两组生长状况、骨代谢指标、胰岛素生长因子水平及不良反应。结果治疗后,两组生长速度(GV)快于治疗前,骨龄(BA)、身高均高于治疗前,且观察组GV快于对照组,BA、身高高于对照组(P<0.05);治疗后,两组骨碱性磷酸酶(BAP)、骨钙素(OC)水平均高于治疗前,且观察组高于对照组(P<0.05);治疗后,两组胰岛素促生长因子(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)水平均高于治疗前,且观察组高于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义。结论采用rhGH治疗矮小症能促进患儿生长发育,提高骨代谢指标水平,调节胰岛素生长因子水平,安全性较高,值得临床推广应用。Objective To investigate the effect of applying recombinant human growth hormone(rhGH)on the clinical efficacy and related factors in the treatment of short stature.Methods 76 children with short stature who were treated in our hospital from February 2019 to June 2020 were selected as the research subjects,and they were divided into observation group and control group according to the random number table method,with 38 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with rhGH on the basis of the control group.The growth status,bone metabolism indexes,insulin growth factor levels and adverse reactions were compared between the two groups.Results After treatment,the growth rate(GV)in the two groups were faster than before treatment,bone age(BA)and height in two groups were higher than before treatment,and the GV in the observation group was faster than control group,the BA and height was higher than control group(P<0.05).After treatment,the bone alkaline phosphatase(BAP)and osteoccalin(OC)levels in two groups were higher than before treatment,and the observation group was higher than control group(P<0.05).After treatment,the insulin-promoting factor(IGF-1)and insulin-like growth factor binding protein 3(IGFBP-3)in two groups were higher than before treatment,and the observation group was higher than control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The use of rhGH in the treatment of short stature can promote the growth and development of children,improve the level of bone metabolism indexes,regulate the level of insulin growth factor,and it is safety,which is worthy of clinical promotion and application.

关 键 词：重组人生长激素 矮小症 临床疗效 骨代谢指标 胰岛素生长因子 

分 类 号：R725.8[医药卫生—儿科]